De-escalated treatment for primary CNS lymphoma
Official title: Optimizing MATRix as Remission Induction in PCNSL: De-escalated Induction Treatment in Newly Diagnosed Primary CNS Lymphoma - a Randomized Phase III Trial
Run by Klinikum Stuttgart · NCT04931368 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new, less intense treatment for people with newly diagnosed primary CNS lymphoma to see if it can help them live longer without cancer events compared to the standard treatment.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 326 (estimated) |
| Sponsor | Klinikum Stuttgart Academic / other |
| Locations | 1 site (Stuttgart, Baden-Württemberg) |
| Trial ID | NCT04931368 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are immunocompetent adults aged 18-70 with newly diagnosed primary diffuse large B-cell lymphoma located exclusively in the CNS.
✕Probably not a fit
Patients with previously treated CNS lymphoma or those with significant comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase III study compares a de-escalated induction treatment for newly diagnosed primary CNS lymphoma against the standard MATRix protocol to determine which approach leads to better event-free survival. Participants in the experimental group will receive one course of Rituximab/HD-Methotrexate followed by two courses of MATRix and autologous stem cell transplantation. In contrast, the control group will undergo four courses of MATRix followed by the same stem cell transplantation. The study aims to identify a potentially less intensive treatment regimen that maintains efficacy while reducing treatment burden.
Why it matters
Potential benefit: If successful, this study could provide a less intensive treatment option for patients with primary CNS lymphoma, potentially improving their quality of life and treatment outcomes.
How similar studies have gone: Other studies have explored de-escalated treatment approaches in various cancers, showing promising results, but this specific approach in primary CNS lymphoma is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Immunocompetent patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system (PCNSL). 2. Male or female patients aged 18-65 years irrespective of ECOG or 66-70 years with ECOG Performance Status ≤2. 3. Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy. 4. Disease exclusively located in the CNS. 5. At least one measurable lesion. 6. Previously untreated patients (previous or ongoing steroid treatment admitted) 7. Negative pregnancy test 8. Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease. 9. Ability to understand the nature of the trial and the trial related procedures and to comply with them. Exclusion Criteria: 1. Congenital or acquired immunodeficiency including HIV infection and previous organ transplantation. 2. Systemic lymphoma manifestation (outside the CNS). 3. Primary vitreoretinal lymphoma without manifestation in the brain parenchyma or spinal cord 4. Previous or concurrent malignancies with the exception of surgically cured carcinoma in situ of the cervix, carcinoma of the skin or other kinds of cancer without evidence of disease for at least 5 years. 5. Previous Non-Hodgkin lymphoma at any time. 6. Inadequate renal function (clearance \< 60 ml/min). 7. Inadequate bone marrow, cardiac, pulmonary or hepatic function according to investigator´s decision 8. Active hepatitis B or C disease. 9. Concurrent treatment with other experimental drugs or participation in an interventional clinical trial with study medication being administered within the last 30 days before the start of this study. 10. Third space fluid accumulation \> 500 ml. 11. Hypersensitivity to study treatment or any component of the formulation. 12. Taking any medications that are likely to cause interactions with the study medication 13. Known or persistent abuse of medication, drugs or alcohol. 14. Active COVID-19-infection or non-compliance with the prevailing hygiene measures regarding the COVID-19 pandemic 15. Patients without legal capacity who are unable to understand the nature, significance and consequences of the trial and without designated legal representative. 16. Previous participation in this trial. 17. Persons who are in a relationship of dependency/employment with the sponsor and/or the investigator. 18. Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule 19. Current or planned pregnancy, nursing period 20. For fertile patients: Failure to use one of the following safe methods of contraception: intra-uterine device or hormonal contraception in combination with a mechanical method of contraception.
Where it's running
-
Klinikum Stuttgart
Stuttgart, Baden-Württemberg, Germany Recruiting
Study contacts
- Principal investigator: Gerald Illerhaus, Prof — Klinikum Stuttgart
- Study coordinator: Gerald Illerhaus, Prof
- Email: g.illerhaus@klinikum-stuttgart.de
- Phone: +4971127830400
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rapid CSF ctDNA Test and Treatment Monitoring for Primary CNS Lymphoma
This study tests whether CSF circulating tumor DNA can quickly diagnose primary CNS lymphoma and monitor response to treatment in adults.
-
Testing a four-drug regimen (methotrexate, rituximab, sintilimab, pirtobrutinib) versus investigator-selected care for newly diagnosed PCNSL
This trial will try a combination of methotrexate, rituximab, sintilimab and pirtobrutinib as first treatment for adults with newly diagnosed primary central nervous system lymphoma to see if it increases complete remissions and is safe compared with standard doctor-selected treatments.
-
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
In this study, adults with newly diagnosed primary CNS lymphoma try different induction regimens to see which one works best before consolidation therapy.
-
Epcoritamab plus ibrutinib for central nervous system lymphoma
This trial tests whether combining epcoritamab and ibrutinib is safe and tolerable for adults with relapsed or refractory primary or secondary central nervous system lymphoma.
-
Tirabrutinib maintenance therapy for patients with primary CNS lymphoma in remission
This study is testing if taking tirabrutinib every day can help people with primary CNS lymphoma stay in remission longer after their initial treatment.
-
Glofitamab after obinutuzumab pre-treatment for central nervous system lymphoma
This trial will test if giving glofitamab after a short obinutuzumab pre-treatment is safe and helpful for adults with primary or secondary central nervous system lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.